张必利,陈翔,徐荣良,秦永文,郑兴,胡建强,马丽萍,吴弘,陈少萍,陈峰,赵仙先

• 1:第二军医大学附属长海医院心内科

摘要(Abstract)：

目的评价优化急性心肌梗死急诊经皮冠状动脉介入治疗(PCI)策略对减少术中无复流现象发生的效果。方法选择2011年6月至2012年6月第二军医大学附属长海医院心内科急性心肌梗死行急诊PCI患者165例,随机分为经验治疗组[血栓负荷重时才使用血栓抽吸装置和(或)使用血小板糖蛋白Ⅱb/Ⅲa抑制剂]和优化治疗组(无论是否血栓负荷重,均使用血小板糖蛋白Ⅱb/Ⅲa抑制剂+血栓抽吸装置)],观察两组术中无复流的发生率。结果经验治疗组和优化治疗组急诊PCI术中无复流的发生率分别为14%和1.16%(P<0.05)。优化治疗组出血并发症未见增加。结论急性心肌梗死急诊PCI优化治疗策略较经验治疗策略明显减少无复流的发生率,不增加出血并发症的风险。

关键词(KeyWords)： 心肌梗死;血管成形术,经腔,经皮冠状动脉;无复流现象;替罗非班

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张必利,陈翔,徐荣良,秦永文,郑兴,胡建强,马丽萍,吴弘,陈少萍,陈峰,赵仙先

参考文献(References)：

• [1]Assali AR,Sdringola S,Ghani M,et al.Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of″no-reflow″phenomenon.Cathet Cardiovasc Interv,2000,51:27-31.
• [2]Morishima I,Sane T,Okumura K,et al.Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.Am Coil Cardiol,2000,36:12022-12029.
• [3]Butler MJ,Chan W,Taylor AJ,et al.Management of the no-reflow phenomenon.Pharmacol Ther,2011,132:72-85.
• [4]Napodano M,Pasquetto G,SaccàS,et al.Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction.J Am Col l Cardiol,2003,42:1395-1402.
• [5]van Ommen V,Michels R,Heymen E,et al.Usefulness of the rescue PT catheter to remove fresh thrombus from coronary arteries and bypass graft s in acute myocardial infarction.Am J Cardiol,2001,88:306-308.
• [6]Limbruno U,De Carlo M,Pistolesi S,et al.Distal embolization during primary angioplasty:histopathologic features and predictability.Am Heart J,2005,150:102-108.
• [7]De Luca G,Navarese EP,Suryapranata H.A meta-analytic overview of thrombectomy during primary angioplasty.Int J Cardiol,2012,doi:10.1016/j.ijcard.2011.11.102.
• [8]Wong P,Harding S,Inglessis I,et al.The effect of glycoproteinⅡb/Ⅲa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stentiong;a prospective,radomized study.J Thromb Thrombolysis,2003,16:163-166.
• [9]Wang Y,Wu B,Shu X.Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoproteinⅡb/Ⅲa inhibitors in patients with ST-elevation myocardial infarction.Am J Cardiol,2012,109:1124-1130.
• [10]Van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME2):a multicentre,double-blind,randomised controlled trial.Lancet,2008,372:537-546.